The estimated Net Worth of Joseph Monahan is at least $1.51 Milhão dollars as of 1 March 2024. Dr Monahan owns over 73,425 units of Aclaris Therapeutics Inc stock worth over $224,571 and over the last 3 years he sold ACRS stock worth over $1,280,699.
Sign up
Dr Monahan ACRS stock SEC Form 4 insiders trading
Dr has made over 16 trades of the Aclaris Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 73,425 units of ACRS stock worth $86,642 on 1 March 2024.
The largest trade he's ever made was exercising 87,175 units of Aclaris Therapeutics Inc stock on 1 March 2023 worth over $102,867. On average, Dr trades about 22,840 units every 59 days since 2021. As of 1 March 2024 he still owns at least 190,314 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Dr Monahan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Joseph Monahan biography
Dr. Joseph Monahan is the Chief Scientific Officer at Aclaris Therapeutics Inc.
What's Dr Monahan's mailing address?
Joseph's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Insiders trading at Aclaris Therapeutics Inc
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol..., eLlc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
What does Aclaris Therapeutics Inc do?
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
What does Aclaris Therapeutics Inc's logo look like?
Complete history of Dr Monahan stock trades at Aclaris Therapeutics Inc
Aclaris Therapeutics Inc executives and stock owners
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Neal Walker,
President, Chief Executive Officer, Co-Founder, Director -
Kamil Ali-Jackson,
Co-Founder, Chief Compliance Officer, Secretary, Chief Legal Officer -
David Gordon,
Chief Medical Officer -
Frank Ruffo,
Co-Founder, Chief Financial Officer -
Dr. Neal S. Walker D.O.,
Co-Founder, CEO, Pres & Director -
Frank Ruffo,
Co-Founder, CFO & Treasurer -
Christopher Molineaux,
Independent Director -
Bryan Reasons,
Independent Director -
Andrew Powell,
Independent Director -
Anand Mehra,
Independent Director -
William Humphries,
Independent Director -
Andrew Schiff,
Independent Director -
Maxine Gowen,
Independent Director -
Vincent Milano,
Director -
James Loerop,
Chief Bus. Officer -
Dr. Paul S. Changelian Ph.D.,
Sr. VP of Biology -
Spencer Brown J.D.,
Sr. VP of Legal Affairs & Compliance Officer -
Dr. Joseph Monahan,
Chief Scientific Officer -
Rick Bierly,
Director -
Ventures Vii, Llc Vivo Vent...,
-
Stephen A. Tullman,
Director -
Albert Cha,
Director -
Stuart Shanler,
Chief Scientific Officer -
Capital Management, Llc Kol...,
-
Christopher Powala,
Chief Operating Officer -
Llc Fmr,
10% owner -
James E Deerfield Mgmt L.P....,
-
Capital Management Iii, Llc...,
-
Brett Fair,
Chief Commercial Officer -
Capital Management, Llc Kol...,
-
Venture Partners Viii, L.P....,
-
Gail Cawkwell,
Chief Medical Officer -
Joseph Monahan,
Chief Scientific Officer -
Douglas J. Manion,
Pres and CEO -
James Loerop,
Chief Business Officer -
Braden Michael Leonard,
-
Kevin Balthaser,
Chief Financial Officer